GLP-1 Drugs, Weight Loss Breakthroughs and Diabetes News Shaping Endocrinology in 2026
From new GLP-1 weight loss data to Omnipod recalls and semaglutide for nicotine addiction, here's what's moving in endocrinology.
Summary
A packed endocrinology news roundup covers several developments relevant to metabolic health. Insulet recalled certain Omnipod insulin pods due to a manufacturing defect causing insulin leakage. Inhaled insulin Afrezza gained FDA approval for children as young as 6. Semaglutide showed mixed results for nicotine addiction in a phase II trial. A new oral dual GLP-1/GIP agonist called ributatide produced up to 12.1% body weight loss by week 26 with no plateau. Osteoporosis was linked to a 47% increased mortality risk in postmenopausal women. Menopausal hormone therapy use dropped significantly from 2007 to 2023. GLP-1 drugs were highlighted for broad anti-inflammatory potential beyond blood sugar control. CVS Caremark reversed course and will again cover Zepbound after patient pushback.
Detailed Summary
This news roundup from MedPage Today covers a wide range of endocrinology and metabolic health developments with direct implications for longevity-focused readers. The breadth of topics — from insulin delivery failures to emerging weight-loss therapies — reflects how rapidly the metabolic health landscape is evolving.
On the diabetes front, Insulet issued a voluntary recall of certain Omnipod pods after a manufacturing defect was found to cause insulin leakage, potentially leaving users undermedicated. Separately, inhaled mealtime insulin Afrezza received FDA approval for children ages 6 and older with type 1 or type 2 diabetes, expanding non-injectable options for pediatric patients.
GLP-1 receptor agonists continue to dominate headlines. A phase II randomized trial in JAMA Network Open showed semaglutide produced mixed results in reducing nicotine addiction. Meanwhile, a Journal of Clinical Endocrinology and Metabolism review positioned GLP-1 drugs as potent anti-inflammatory agents with therapeutic potential far beyond glucose control. New weight-loss data from Kailera Therapeutics showed oral ributatide achieving up to 12.1% body weight reduction by week 26 with no plateau — a promising signal for the next generation of oral obesity drugs.
In women's health, osteoporosis was associated with a 47% increased mortality risk in postmenopausal women based on national survey data, underscoring the underappreciated lethality of bone density loss. Menopausal hormone therapy use dropped sharply from 4.4% in 2007 to 1.7% in 2023, a trend with potential downstream consequences for bone, cardiovascular, and cognitive health in aging women.
Caveats apply throughout: this is a news digest, not a deep-dive into any single study. Many findings are from early-phase trials or observational data. Readers should consult primary sources before drawing clinical conclusions.
Key Findings
- New oral GLP-1/GIP agonist ributatide achieved up to 12.1% body weight loss by week 26 with no plateau in phase II trial.
- Semaglutide showed mixed results for reducing nicotine addiction in a randomized phase II trial published in JAMA Network Open.
- Osteoporosis linked to 47% increased mortality risk in postmenopausal women based on national survey data.
- GLP-1 medications reviewed as potent anti-inflammatory agents with broad therapeutic applications beyond diabetes and obesity.
- Menopausal hormone therapy use in women 40+ dropped from 4.4% to 1.7% between 2007 and 2023.
Methodology
This is a curated news digest by a senior MedPage Today staff writer, aggregating multiple recent developments across endocrinology. Sources cited include peer-reviewed journals such as JAMA Network Open, The Lancet Diabetes and Endocrinology, and the Journal of Clinical Endocrinology and Metabolism, alongside FDA alerts and company announcements. Evidence quality varies by item, ranging from phase I/II trial data to observational claims analyses.
Study Limitations
This is a news roundup, not a primary research article, so depth on any single finding is limited. Several cited studies are early-phase trials with small samples and no long-term follow-up data. Readers should consult original publications and healthcare providers before making clinical decisions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.